ID   OCM-3
AC   CVCL_6937
SY   OCM3; Ocm3; ocm-3
DR   BioSample; SAMN06481119
DR   cancercelllines; CVCL_6937
DR   Cosmic; 916142
DR   Cosmic; 1320369
DR   Cosmic; 1628409
DR   Cosmic; 2163831
DR   Wikidata; Q54931808
RX   PubMed=16772116;
RX   PubMed=18689700;
RX   PubMed=19340423;
RX   PubMed=22236444;
RX   PubMed=23851445;
CC   Problematic cell line: Contaminated. Shown to be a SK-MEL-28 derivative (PubMed=22236444 and STR profile from PubMed=18689700). Originally thought to originate from an uveal melanoma.
CC   From: Kan-Mitchell J.; Wayne State University; Detroit; USA.
CC   Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00503.
CC   Population: Caucasian.
CC   Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Homozygous (PubMed=22236444; PubMed=23851445).
CC   Sequence variation: Mutation; HGNC; 1773; CDK4; Simple; p.Arg24Cys (c.70C>T); ClinVar=VCV000016928; Zygosity=Heterozygous (PubMed=23851445).
CC   Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Pro753Ser (c.2257C>T); ClinVar=VCV000376081; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Thr167Ala (c.499A>G); ClinVar=VCV001686107; Zygosity=Homozygous (PubMed=23851445).
CC   Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.-57A>C (c.161A>C) (A161C); ClinVar=VCV000242210; Zygosity=Unspecified; Note=In promoter (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Leu145Arg (c.434_435TG>GT); Zygosity=Homozygous (PubMed=23851445).
CC   Derived from site: In situ; Skin; UBERON=UBERON_0002097.
CC   Cell type: Melanocyte of skin; CL=CL_1000458.
ST   Source(s): ESTDAB; PubMed=18689700
ST   Amelogenin: X,Y
ST   CSF1PO: 10,12
ST   D13S317: 11,12
ST   D16S539: 9,12
ST   D18S51: 12,16
ST   D21S11: 28,29
ST   D3S1358: 16,18
ST   D5S818: 11,13
ST   D7S820: 10
ST   D8S1179: 13
ST   FGA: 19
ST   TH01: 7
ST   TPOX: 8,12
ST   vWA: 16,19
DI   NCIt; C3510; Cutaneous melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0526 ! SK-MEL-28
SX   Male
AG   51Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 33
RX   PubMed=16772116; DOI=10.1016/j.cancergencyto.2005.11.016;
RA   White J.S., Becker R.L., McLean I.W., Director-Myska A.E., Nath J.;
RT   "Molecular cytogenetic evaluation of 10 uveal melanoma cell lines.";
RL   Cancer Genet. Cytogenet. 168:11-21(2006).
RX   PubMed=18689700; DOI=10.1167/iovs.08-2324;
RA   Folberg R., Kadkol S.S., Frenkel S., Valyi-Nagy K., Jager M.J.,
RA   Pe'er J., Maniotis A.J.;
RT   "Authenticating cell lines in ophthalmic research laboratories.";
RL   Invest. Ophthalmol. Vis. Sci. 49:4697-4701(2008).
RX   PubMed=19340423; DOI=10.1007/s00262-009-0701-z;
RA   Mendez R., Aptsiauri N., Del Campo A., Maleno I., Cabrera T.,
RA   Ruiz-Cabello F., Garrido F., Garcia-Lora A.;
RT   "HLA and melanoma: multiple alterations in HLA class I and II
RT   expression in human melanoma cell lines from ESTDAB cell bank.";
RL   Cancer Immunol. Immunother. 58:1507-1515(2009).
RX   PubMed=22236444; DOI=10.1111/j.1755-148X.2012.00971.x;
RA   Griewank K.G., Yu X.-X., Khalili J., Sozen M.M., Stempke-Hale K.,
RA   Bernatchez C., Wardell S., Bastian B.C., Woodman S.E.;
RT   "Genetic and molecular characterization of uveal melanoma cell
RT   lines.";
RL   Pigment Cell Melanoma Res. 25:182-187(2012).
RX   PubMed=23851445; DOI=10.1158/1541-7786.MCR-13-0006;
RA   Dahl C., Christensen C., Jonsson G., Lorentzen A., Skjodt M.L.,
RA   Borg A., Pawelec G., Guldberg P.;
RT   "Mutual exclusivity analysis of genetic and epigenetic drivers in
RT   melanoma identifies a link between p14 ARF and RARbeta signaling.";
RL   Mol. Cancer Res. 11:1166-1178(2013).